Heart FailureCVD-PHPTNCT07870369
Cardiovascular Risk in Patients With Primary Hyperparathyroidism
An observational study of Heart Failure and Atrial Fibrillation (AF), run by Medical University of Sofia at 1 site in Bulgaria.
Trial summary
Patients with primary hyperparathyroidism versus healthy controls assessed for their cardiovascular risk and overt CVD Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Heart Failure, Atrial Fibrillation (AF), Arrhythmia
- How many people
- 77 participants
- Where
- 1 siteBulgaria
- Study dates
- 1 Jan 2023to 31 Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: 54 patients with PHPT and 23 controls
Who may be able to join
- confirmed primary hyperparathyroidism
Who cannot join
- secondary hyperparathyroidism
Trial locations and contacts
1 site in 1 country.
About this study
Patients with primary hyperparathyroidism versus healthy controls assessed for their cardiovascular risk and overt CVD
Read the detailed description
A cross-sectional, non-interventional single-center study includding 54 patients with primary hyperparathyroidism and 23 healthy controls. The participants have been examined clinically and with certain instrumental investigations: laboratorys, ECG, Holter ECG echocardiography. We have evaluated comparatively the cardiovascular risk and the over cardiac events in both groups and sought for determinants of cardiaovascular complications in primary hyperparathyoridism.
- Conditions
- Heart Failure, Atrial Fibrillation (AF), Arrhythmia, Coronary Artery Disease, Hypertension (HTN)
- Keywords
- primary hyperparathyoidism, cardiovascular, risk, arrhythmias, hypertension, heart failure
- Medical subject headings
- Heart Failure, Atrial Fibrillation, Arrhythmias, Cardiac, Coronary Artery Disease, Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Primary hyperparathyroidism | Patients with primary hyoerparathyroidism | |
| Control group | Patients withthout primary pyperparathyroidism mateched for age and sex |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cardiovascular events
Any cardiac events
Measured: 24 months
Cardiovascular complications
Any cardiovascular disease
Measured: january 1st 2023 - december 31st 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Oct 2026
- Study start1 Jan 2023
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 77 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medical University of Sofia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Stefan Naydenov Naydenov, Medical University of Sofia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07870369
- Sponsor's protocol ID
- PHPT-CVD-2023
- Acronym
- CVD-PHPT
- Status last verified
- Oct 2026
- First submitted
- 6 Oct 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cardiovascular Risk in Patients With Primary Hyperparathyroidism
- ClinicalTrials.gov ID
- NCT07870369
- Acronym / sponsor ID
- CVD-PHPT / PHPT-CVD-2023
- Conditions
- Heart Failure, Atrial Fibrillation (AF), Arrhythmia, Coronary Artery Disease, Hypertension (HTN)
- Keywords
- primary hyperparathyoidism, cardiovascular, risk, arrhythmias, hypertension, heart failure
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 77 participants (actual)
- Lead sponsor
- Medical University of SofiaUniversity, hospital or other
- Study start
- 1 Jan 2023 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 13 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with primary hyperparathyroidism versus healthy controls assessed for their cardiovascular risk and overt CVD
Detailed description
A cross-sectional, non-interventional single-center study includding 54 patients with primary hyperparathyroidism and 23 healthy controls. The participants have been examined clinically and with certain instrumental investigations: laboratorys, ECG, Holter ECG echocardiography. We have evaluated comparatively the cardiovascular risk and the over cardiac events in both groups and sought for determinants of cardiaovascular complications in primary hyperparathyoridism.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Primary hyperparathyroidism | – | –Patients with primary hyoerparathyroidism |
| Control group | – | –Patients withthout primary pyperparathyroidism mateched for age and sex |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- 54 patients with PHPT and 23 controls
Key inclusion criteria (1 listed)
- confirmed primary hyperparathyroidism
Key exclusion criteria (1 listed)
- secondary hyperparathyroidism
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cardiovascular events
Time frame: 24 months
Any cardiac events
Cardiovascular complications
Time frame: january 1st 2023 - december 31st 2025
Any cardiovascular disease
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Individual participant dataSharing planned: Yes
Related trials for Heart Failure
RecruitingPhase 3
Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload
Acute Heart Failure
RecruitingObservational study
Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure
Heart Failure, Muscle Atrophy
Enrolling by invitationObservational study
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Heart Failure
Recruiting
Renal Denervation in Patients With Atrial Fibrillation and Hypertension
Atrial Fibrillation (Paroxysmal), Hypertension
Recruiting
Assessment of CCM in HF With Higher Ejection Fraction
Heart Failure, Heart Failure With Preserved Ejection Fraction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Heart Failure and Atrial Fibrillation (AF), run by Medical University of Sofia at 1 site in Bulgaria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Bulgaria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cardiovascular events (time frame: 24 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.